Chemotherapy Compounding Drug Development 
STAT
OCTOBER 20, 2023
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.
Express Pharma
APRIL 3, 2023
The diagnosed prevalent cases of gastric, breast, and bladder cancers in China are expected to increase at a compound annual growth rate (CAGR) of 2.6 These companies have active research and development collaborations with various local players worldwide. per cent, 1.6 per cent, and 3 per cent, respectively, between 2022 and 2028.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 5, 2022
Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.
Pharmaceutical Technology
FEBRUARY 24, 2023
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pharmaceutical Technology
AUGUST 12, 2022
By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. The standard first-line treatment for DLBCL is a chemotherapy regimen, alongside the monoclonal antibody rituximab. There are a total of 124 companies involved in CAR-T cell drug development for this indication.
Pharmaceutical Technology
FEBRUARY 13, 2023
This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. Faslodex will be administered in the control arm of the Phase III study, allowing for direct comparison between the two ER degraders.
European Pharmaceutical Review
JULY 5, 2022
The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. New hope for stomach cancer patients.
Expert insights. Personalized for you.
319 
Let's personalize your content